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Abstract. Ten patients treated with electroconvulsive therapy (ECT) only were 
followed with serial sleep polysomnographic recordings and dexamethasone 
suppression tests (DSTs). Both biological correlates of depression showed 
improvement with ECT. The use of serial sleep measures and serial DSTs in 
monitoring the clinical response to ECT is discussed. 
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Electroconvulsive therapy (ECT) continues to be one of the most effective forms of 
treatment for severe, psychotic, or medication-nonresponsive major depressive 
disorder (MDD) (APA Task Force Reporf #/4. 1978). Although the use of ECT 
declined with the development of antidepressant medications, interest in this 
treatment modality has renewed in recent years (Consensus Devrlopment 
Conjh-ence Statement, National Institutes of Health, 1985). While the literature on 
biological correlates of affective disorders has grown in size and complexity, 
published studies of ECT patients are relatively few. This scarcity of studies 
concerning patients undergoing ECT probably reflects the practical difficulties of 
conducting research in severely ill patients. Nevertheless, some reports indicate that 
both the dexamethasone suppression test (DST) (Carroll, 1972; Dysken et al., 1979; 
Albala et al., 1981; Papakostas et al., 1981; Coryell and Zimmerman, 1983; 
Yerevanian et al., 1983; Nemeroff and Evans, 1984; Coryell, 1986; McAllister and 
Price, 1986; Grunhaus et al., 1987) and sleep electroencephalography (EEG) 
(Grunhaus et al., 1985; Hoffman et al., 1985) may be valuable in monitoring the 
antidepressant effects of ECT. 
Initial reports were enthusiastic about the ability of the DST to monitor response 
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to ECT, suggesting that favorable response to ECT would be accompanied by 
normalization of the DST (Carroll, 1972; Dysken et al., 1979; Albala et al., 1981). 
Those failing to respond to the treatment would continue to show the 
nonsuppressive response. More recent communications (Coryell, 1986; Grunhaus et 
al., 1987) have been tempered by caution, but do not rule the DST out as a 
potentially useful tool in monitoring ECT response. 
Sleep polysomnography has also been studied extensively in affective disorders, 
and many changes believed to be characteristic of MDD have been described 
(Kupfer, 1976; Kupfer et al., 1978; Feinberg et al., 1982). These abnormalities appear 
to be more frequent in the severely depressed or psychotically depressed patients who 
are often referred for ECT. In these situations, patients may show even more 
disrupted sleep with frequent arousals and early morning awakening, very short 
rapid eye movement (REM) latency or sleep onset REM periods (SOREM), and 
high REM density (Thase et al., 1986). Surprisingly, very few modern studies have 
used serial studies of the sleep electroencephalogram (EEG) to monitor the progress 
of patients undergoing ECT. Grunhaus et al. (1985) and Hoffmann et al. (1985) 
have described the normalization of sleep EEG abnormalities in MDD patients 
after ECT. 
The present report replicates and expands our previous study on the changes of 
sleep parameters with ECT. Interestingly, 2 of the current sample of 10 patients were 
considered nonresponders to treatment; these patients did not show normalization of 
the pretreatment abnormal biological correlates. 
Methods 
Ten inpatients (four males and six females, ages ranging from 44 to 77 with a mean of 61.5 
years) from the Clinical Studies Unit of the University of Michigan Hospitals were included in 
the study. All were evaluated according to our standard protocol, which includes: (I) 12-14 
days of drug-free observation; (2) several diagnostic interviews by senior psychiatrists and the 
complete Schedule for Affective Disorders and Schizophrenia (Spitzer and Endicott, 1975); 
(3) a diagnostic family interview corroborating anamnestic information; (4) a review of all past 
medical records as available; and (5) a complete medical and laboratory workup. At the end of 
the observation period, diagnosis was made by consensus of all clinicians involved using the 
Research Diagnostic Criteria (RDC) (Spitzer et al., 1978). 
To be included in the study, patients were required to (I) meet the diagnosis of MDD, (2) 
have been free from psychotropic drugs for at least I2 days, (3) not have an illness or have 
received medications that would preclude the sleep-EEG recordings, (4) have been treated 
with ECT only without other medications than those required for the anesthesia/muscular 
relaxation process, and (5) have agreed to participate in serial sleep EEG recordings and blood 
drawing for the DST. The clinical indications for ECT were severe depression, presence of 
delusional features, and either previous poor response to antidepressant medications or 
previous good response to ECT. 
Unilateral nondominant ECT was administered three times a week with a Medcraft 
instrument. Treatment parameters were set to achieve seizure activity (recorded with the cuff 
method) of at least 25-set duration. Restimulation was performed whenever seizures were 
absent or too short. Standard anesthetic pretreatment included the use of a quaternary 
anticholinergic agent (glycopyrrolate), a short-acting barbiturate (methohexital), and a muscle 
relaxant (succinylcholine). The length of the ECT course was determined by clinicians without 
knowledge of the research data. No antidepressant, antipsychotic, or sedative hypnotic agents 
were administered concurrently with the treatments. One patient required 5 mg of diazepam 
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for post-ECT agitation; the post-ECT sleep recordings in this patient were performed I2 days 
from the last dose of minor tranquilizers. 
Two consecutive nights of sleep were recorded following the drug-free period with subjects 
sleeping in their own hospital bed (patients 2 and 4 in Table I could tolerate only night 2 of 
recording). Placement of electrodes and scoring were done according to the method of 
Rechtschaffen and Kales (1968). The following definitions were applied when studying the 
sleep recordings: time asleep (TS-A): time (min) from sleep onset to end of sleep minus awake; 
total recordingperiod (TRP): time (min) from beginning of recording (“lights out”) to end of 
recording; awake: time (min) awake between sleep onset and end of sleep; delta sleep: stages 
III and IV; early morning awakening (EMA): time (min) awake between end of sleep and 
arising (end of recording); REM activity (RA): the sum of the eye movement scores during 
REM sleep for the entire night, based on a score of O-8 for each min of REM sleep; REM 
density: REM activity/REM time (RA/RT); REM latency: time (min) from sleep onset to 
onset of stage REM; REM latency minus awake (RLMA): REM latency minus any time 
awake between sleep onset and REM onset (min); REM percent (REM%): RT/(TS - A) X 
100%; REM time (RT): time (min) spent in stage REM; sleep ej’ciency: (TS - A)/TRP X 
100gI; sleep latency: time (min) from beginning of recording to sleep onset; REM period: a 
period containing at least three I-min epochs of REM sleep, with not more than 30 min of 
non-REM sleep between any two epochs of REM; sleep onset: 2 3 min of continuous REM 
sleep, or IO consecutive min of sleep with the first min being stage 2,3,4, or REM sleep and at 
most I min of time awake during this IO-min period. 
Two nights of post-ECT sleep EEG recordings (patient 7 in Table I could tolerate only I 
night of recording) were performed following the same guidelines as the pre-ECT tracings, 
with the patient sleeping in his own bed and before beginning maintenance psychotropics. 
Post-ECT sleep recordings were done I-4 days after the last ECT. 
It is unclear whether the medications used during the ECT procedure. affect sleep EEG 
recordings. Glycopyrrolate and succinylcholine do not cross the blood-brain barrier and 
therefore would not be expected to have central effects. Methohexital, on the other hand, 
could have definite effects on sleep EEG recordings. To circumvent this problem, we recorded 
our patients at least 36 hours after the anesthesia. Nevertheless, the possibility that repeated 
anesthesia, however brief, might affect sleep EEG recordings needs to be kept in mind. 
The clinical status of the patients was rated weekly with the l7-item Hamilton Rating Scale 
for Depression (HRSD) (Hamilton, 1960). We defined treatment outcome as follows: good 
response-final HRSD < IO; poor response-final HRSD > IO. Ratings were performed 
within 48 hours of the sleep recordings. Clinicians had no knowledge of sleep EEG results 
throughout the treatment period, and sleep EEG raters were requested to refrain from 
inquiring about the patients’clinical progress while they were performing and scoring the sleep 
EEG recordings. 
The I mg overnight DSTs were performed following the guidelines of Carroll et al. 
(1981). All patients had been drug free for IO-14 days before the DST, and no exclusion 
criteria for the DST were present in any of the patients. Blood was drawn at 8 a.m., 4 p.m., 
and I I p.m. the day after the administration of I mg dexamethasone. The results presented are 
the maximal postdexamethasone cortisol levels observed among the three samples. DSTs were 
performed on different days than the sleep recordings. 
The pre- and post-ECT sleep EEG results were compared by paired t tests. One of the 
patients was a nonresponder, and another patient relapsed 3 weeks after the end of the ECT 
course in spite of appropriate tricyclic antidepressant maintenance. These two patients were 
considered nonresponders to treatment in the analysis. 
Results 
Table 1 shows the demographic, clinical, and laboratory information of the patients. 
All were diagnosed as MDD endogenous subtype according to the RDC, and three 
























































































































































































































































































































































































































































































































































































































































































ranged between 5 and 14, with a mean of 9.6; nine of the ECT series were unilateral 
and one was bilateral. The HRSD shows that all patients were significantly 
depressed and that all but one showed a dramatic response to ECT. A paired t-test 
analysis for the HRSD scores showed a very significant difference between the 
pre-and post-ECT scores (p < O.OOl), with the mean for the pre-ECT being 26.8 and 
that for the post-ECT being 7.7 with a standard deviation of 10.8. 
The DST results show that 5 of the IO patients were nonsuppressors before ECT 
and that all patients were suppressors following the course of ECT. Paired-t analysis 
on the log-transformed values of the maximal postdexamethasone plasma cortisol 
showed a significant drop for the post-ECT time point (p < 0.01) (mean pre-ECT 
log-transformed cortisol was 1.8; mean post-ECT log-transformed cortisol was 1 .O; 
the standard deviation was 0.7). Pre-ECT REM latency and REM density scores 
were consistent with those reported for MDD endogenous patients with the 
exception of patient 6, who showed a REM latency within normal range, but high 
REM density. The striking change observed with ECT on the sleep parameters is 
seen individually in Table I and in more detail with group means in Table 2. 
Table 2. Mean sleep variables pre- and post-ECT 
Sleep 
variables Pre-ECT Post-ECT SD 
Paired 
t 
Sleep TRP 429.3 (424.3)’ 
continuity EMA 12.2 ( 12.6) 
measures Sleep latency 51.6 ( 54.5) 
Arousals 6.8 ( 10.1) 
Awake 92.2 (105) 
TSA 278 (257) 
A.TSA% 21.9 ( 24.5) 
Sleep efficiency 64.4 ( 60.3) 
Sleep Stage 1 67.4 ( 66.6) 
architecture Stage 2 143 (128.1) 
Stage 3 4.5 ( 5.6) 
Stage 4 0 ( 0) 
Delta 4.5 ( 5.6) 
Delta % 1.6 ( 2.0) 
Stage 1% 28 ( 29.9) 
REM measures REM latency 19.8 ( 20.1) 
RLMA 17.1 ( 16.8) 
REM% 22.8 ( 22.6) 
REM time 62.5 ( 57.1) 
REM activity 193.8 (190) 
RA.TSA 0.7 ( 0.7) 
REM density 3 ( 3.2) 
453 (465.3) 
12.7 ( 15.4) 
32.6 ( 36) 
5.7 ( 5.1) 
30.6 ( 31.1) 
375.9 (381.5) 
9 ( 9.4) 
83 ( 81.7) 
77 ( 63.1) 
207.5 (220.6) 
9.2 ( 9.5) 
0.2 ( 0.12) 
9.4 ( 9.6) 
2.3 ( 2.7) 
20.9 ( 17.3) 
78.6 ( 60.3) 
75.5 ( 58.1) 
22.1 ( 23.2) 
82 ( 88.1) 
175.7 (191.3) 
0.5 ( 0.5) 
2.2 ( 2.2) 
47.5 ( 32.6) 
15.3 ( 15.5) 
24.6 ( 26.1) 
8.5 ( 8) 
104.1 (113.9) 
97 ( 85.1) 
11 ( 11.1) 
16.5 ( 16.9) 
55.5 ( 32.6) 
79.2 ( 58.1) 
13.6 ( 14.7) 
0.4 ( 0.4) 
13.5 ( 14.4) 
4.2 ( 4.5) 
18.1 ( 12.3) 
77.2 ( 16.1) 
72.2 ( 13.3) 
8.6 ( 5.1) 
34.4 ( 17.8) 
101.5 ( 91.6) 
0.3 ( 0.3) 
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l * (“1 
Abbreviafions. ECT = electroconvulsive therapy. REM = rapid eye movement. TRP = total recording period. 
EMA == early morning awakening. TSA = time spent asleep. A.TSA% = ratio of awake time after sleep onset to 
total min of actual sleep %. RLMA = REM latency minus awake. RA.TSA = ratio of total REM activity to time 
asleep. 
* = p << 0.05. **=p<o.oi. *** = p < 0.001 
1. Values in parentheses correspond to treatment responders only (n = 8) 
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The specific sleep EEG measurements are presented in Table 2. The scores for the 
treatment responders (n = 8) are presented in parentheses following the mean for the 
whole group. Sleep continuity measurements improved significantly after ECT, 
particularly sleep latency (p < 0.05) time asleep (p < O.Ol), and % awake (p < 0.05), 
and Stage 1% significantly decreased @ < 0.05). REM-related measures were the 
most dramatically affected by ECT, particularly when the analysis was performed 
with the treatment responders alone. REM latency, REM latency minus awake, 
REM time, and REM density all changed significantly (p < 0.05 or 0.01) when the 
whole group was considered and even more so for some variables 0, < 0.001) when 
just responders were considered. 
Discussion 
This study confirms our previous report (Grunhaus et al., 1985) and that of 
Hoffmann et al. (1985) on the favorable effects of ECT on sleep measures of MDD 
patients. These effects are seen at all levels, including sleep continuity, sleep 
architecture, and REM-related sleep measurements. Of the two nonresponders, one 
showed no clinical change, normalized his DST, yet showed no change in REM 
latency and REM density. Patient 5 (Table 2) received only five ECTs and showed a 
dramatic positive response, but REM values were more abnormal in the post-ECT 
recordings. As noted before, this patient relapsed within 3 weeks of ending ECT. The 
DST results for this patient showed normal suppression both before and after 
treatment. 
Hoffmann et al. (1985) mention that one of their patients did not respond to ECT 
clinically but nevertheless showed improved sleep recordings. They suggest that this 
disparity may be due to an effect of ECT on sleep mechanisms regardless of 
treatment response. In our sample, the evidence is different: those patients who failed 
to respond to ECT showed a corresponding lack of improvement on most of the 
sleep parameters explored. Hoffmann et al. do not mention their definition for 
treatment response, but their raw HRSD scores suggest that some of the patients 
would have been categorized as either partial responders or nonresponders by more 
standardized methods of defining treatment response (Coryell, 1982; Greden et al., 
1983). At any rate, studies with larger samples are needed to clarify this point. 
Our sleep findings support previous published reports of the favorable effects of 
ECT on sleep parameters (Green and Stajduhar, 1966; Hawkins et al., 1967; 
Zarcone et al., 1967; Van de Castle and Hawkins, 1969; Mendels et al., 1974). Very 
few reports using conventionally accepted methods of sleep recording had been 
published until our report (Grunhaus et al., 1985) and that of Hoffmann et al. (1985). 
Methodological differences, such as the definitions of sleep parameters and the 
length of the drug-free period preceding the EEG recording, make comparisons with 
previous studies very difficult. Nevertheless, Green and Stajduhar (1966) reported a 
case of a psychotically depressed patient whose dream latency showed a significant 
delay after ECT. Our findings basically corroborate this report. 
As mentioned, we found significant improvements in some of the sleep EEG 
parameters of patients undergoing ECT. Thus, sleep EEG findings appear to be state 
dependent and to improve with change in the clinical condition. Rush et al. (1986) 
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and Puig-Antich et al. (1985) have reported, both in adults and adolescents, that 
sleep EEG findings during a depressive episode are not necessarily state related. 
These authors studied depressed patients before treatment with antidepressants and 
after withdrawal from antidepressants following recovery. They reported that sleep 
EEG abnormalities persisted after the withdrawal from antidepressant medication. 
These authors suggest that sleep EEG abnormalities in their patients might reflect an 
underlying trait feature, which in turn may be related to a higher risk for depression. 
Some of the differences between the study we are reporting and those by Rush et al. 
and Puig-Antich et al. may relate to the severity of the depression and the degree of 
decreased REM latency. Our patients were markedly depressed, and seven of them 
had REM latencies below 10 min. The patients of Rush et al. and Puig-Antich et al. 
were less severely ill and had longer REM latencies. 
The DST was initially proposed as an effective diagnostic tool in MDD. More 
recently, it has come under sharp criticism, and its applicability in the diagnosis of 
MDD has been questioned (Arana et al., 1985; Stokes, 1987). Nevertheless, its 
potential use for the monitoring of antidepressant response is still viewed positively 
(Arana et al., 1985), even though some contradictory evidence has been published. 
To our knowledge, the validity of the DST in a very sick population of depressives 
has yet to be evaluated prospectively. Patients referred for ECT may constitute a 
good sample for this study. It may well be that in groups with a higher sensitivity for 
the DST, such as severely depressed or psychotic patients, the applicability of the 
DST in monitoring treatment response may be greater. In this sample of patients, 
DST findings normalized in all of the initial nonsuppressors, including a non- 
responder to ECT. 
The practical applications of the sleep findings we have reported are difficult to 
assess. On the one hand, ECT is a major psychiatric procedure performed on 
severely ill patients. The need for laboratory tests that could monitor antidepressant 
response is particularly great for this group of patients. On the other hand, sleep 
EEG measures have many restrictions, both economical and clinical (e.g., the length 
of the drug-free period and patient compliance), that limit their clinical applicability. 
Our preliminary findings suggest that it may be worthwhile, particularly in those 
patients with a severe illness, to monitor sleep EEG change occurring with ECT. 
Prospective study of larger samples of patients, including a followup period after 
hospital discharge and comparisons with age-matched controls, may provide us with 
the information necessary to make a more reliable judgment on this very important 
question. 
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